Compositions comprising extracts or materials derived from palm oil vegetation liquor for inhibition of vision loss due to angiogenesis and method of preparation there

Abstract

The present invention relates generally to a composition comprising palm fruit juice for use in a method of preventing and inhibiting vision loss due to angiogenesis related diseases. The composition of the present invention aids to decrease in CNV size using confocal microscopy, in addition to reduction in macrophage infiltration using immune staining; decrease in VEGF-A-induced angiogenesis using established cornea pocket assay, inhibition of IKB-D phosphorylation in laser treated choroidal tissues and reduction in macrophage recruitment to CNV lesions.

1 . A composition comprising an effective amount of an extract derived from palm oil vegetation liquor so as to prevent or inhibit vision loss due to angiogenesis associated disease. 
     
     
         2 . The composition as claimed in  claim 1  wherein the extract is a water soluble component derived from palm oil vegetation liquor. 
     
     
         3 . The composition as claimed in  claim 1  wherein the extract contains phenolics. 
     
     
         4 . The composition as claimed in  claim 1  wherein the extract is palm fruit juice. 
     
     
         5 . The composition according to  claim 1 , wherein the angiogenesis associated disease is an ocular angiogenesis associated disease. 
     
     
         6 . The composition according to  claim 1 , wherein the angiogenesis associated disease is macular degeneration. 
     
     
         7 . The composition according to  claim 5 , wherein the ocular angiogenesis associated disease is age-related macular degeneration (AMD). 
     
     
         8 . The composition according to  claim 7 , wherein an effective amount of the composition is used to reduce the size of choroidal neovascularization (CNV) lesions in AMD. 
     
     
         9 . The composition according to  claim 7 , wherein an effective amount of the composition is used to reduce macrophage infiltration in AMD. 
     
     
         10 . The composition according to  claim 1 , wherein an effective amount of the composition is used to suppress VEGF-A-induced angiogenesis. 
     
     
         11 . The composition according to  claim 7 , wherein an effective amount of the composition is used to suppress pro-inflammatory signaling in AMD. 
     
     
         12 . The composition according to  claim 2 , wherein an effective amount of the composition is used to inhibit IKB-α phosphorylation in choroidal tissues. 
     
     
         13 . The composition according to  claim 7 , wherein an effective amount of the composition is used to reduce macrophage recruitment to CNV lesions in AMD. 
     
     
         14 . The composition according to  claim 1 , wherein an effective amount of the composition is used to inhibit vision loss due to diseases associated with VEGF receptor phosphorylation. 
     
     
         15 . The composition according to  claim 1 , wherein an effective amount of the composition is used to inhibit vision loss due to ocular neovascularization. 
     
     
         16 . A method for the prevention of vision loss due to angiogenesis related disease, said method comprising administering the composition of  claim 1  to a patient in need thereof. 
     
     
         17 . The method as claimed in  claim 16 , wherein the angiogenesis related disease is associated with macular degeneration. 
     
     
         18 . The method as claimed in  claim 16 , wherein the disease is age-related macular degeneration (AMD). 
     
     
         19 . The method as claimed in  claim 16 , wherein an effective amount of the composition is used to provide protective effects against glaucoma, diseases associated with glaucoma, or corneal transplants. 
     
     
         20 . The method as claimed in  claim 16 , wherein an effective amount of the composition is used to provide protective effects against diabetic retinopathy and diseases associated thereto. 
     
     
         21 .- 25 . (canceled)